Uric acid and risk of heart failure: a systematic review and meta-analysis. 2014

He Huang, and Baotao Huang, and Yulin Li, and Yan Huang, and Jing Li, and Hongmei Yao, and Xianchao Jing, and Jianrong Chen, and Ji Wang
Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China.

OBJECTIVE We aimed to perform a systematic review and meta-analysis to assess the association between serum uric acid and incident heart failure (HF)/prognosis of HF patients. RESULTS A systematic electronic literature search was conducted in Embase (Ovid SP, from 1974 to May 2013), Medline (Ovid SP, from 1946 to May 2013), and the Chinese Biomedical Literature Database (CBM, from 1978 to May 2013) to identify studies reporting on the association between serum uric acid and HF. Either a random effects model or a fixed effects model was used for pooling data. Five studies reporting on incident HF and 28 studies reporting on the adverse outcomes of HF patients were included. The results showed that hyperuricaemia was associated with an increased risk of incident HF [hazard ratio (HR) 1.65, 95% confidence interval (CI) 1.41-1.94], and the risk of all-cause mortality (HR 2.15, 95% CI 1.64-2.83), cardiovascular mortality (HR 1.45, 95% CI 1.18-1.78), and the composite of death or cardiac events (HR 1.39, 95% CI 1.18-1.63) in HF patients. For every 1 mg/dL increase in serum uric acid, the odds of development of HF increased by 19% (HR 1.19, 95% CI 1.17-1.21), and the risk of all-cause mortality and the composite endpoint in HF patients increased by 4% (HR 1.04, 95% CI 1.02-1.06) and 28% (HR 1.28, 95% CI 0.97-1.70), respectively. Subgroup analyses supported the positive association between serum uric acid and HF. CONCLUSIONS Elevated serum uric acid is associated with an increased risk of incident HF and adverse outcomes in HF patients.

UI MeSH Term Description Entries
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D006333 Heart Failure A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION. Cardiac Failure,Heart Decompensation,Congestive Heart Failure,Heart Failure, Congestive,Heart Failure, Left-Sided,Heart Failure, Right-Sided,Left-Sided Heart Failure,Myocardial Failure,Right-Sided Heart Failure,Decompensation, Heart,Heart Failure, Left Sided,Heart Failure, Right Sided,Left Sided Heart Failure,Right Sided Heart Failure
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor
D014527 Uric Acid An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN. 2,6,8-Trihydroxypurine,Ammonium Acid Urate,Monosodium Urate,Monosodium Urate Monohydrate,Potassium Urate,Sodium Acid Urate,Sodium Acid Urate Monohydrate,Sodium Urate,Sodium Urate Monohydrate,Trioxopurine,Urate,Acid Urate, Ammonium,Acid Urate, Sodium,Acid, Uric,Monohydrate, Monosodium Urate,Monohydrate, Sodium Urate,Urate Monohydrate, Monosodium,Urate Monohydrate, Sodium,Urate, Ammonium Acid,Urate, Monosodium,Urate, Potassium,Urate, Sodium,Urate, Sodium Acid
D014943 Global Health A multi- and interdisciplinary field concerned with improving health and achieving equity in health for all people. It transcends national boundaries, promotes cooperation and collaboration within and beyond health science fields, and combines population-based disease prevention with individually-based patient care. International Health Problems,World Health,International Health,Worldwide Health,Health Problem, International,Health Problems, International,Health, Global,Health, International,Health, World,Health, Worldwide,Healths, International,International Health Problem,International Healths,Problem, International Health,Problems, International Health
D015994 Incidence The number of new cases of a given disease during a given period in a specified population. It also is used for the rate at which new events occur in a defined population. It is differentiated from PREVALENCE, which refers to all cases in the population at a given time. Attack Rate,Cumulative Incidence,Incidence Proportion,Incidence Rate,Person-time Rate,Secondary Attack Rate,Attack Rate, Secondary,Attack Rates,Cumulative Incidences,Incidence Proportions,Incidence Rates,Incidence, Cumulative,Incidences,Person time Rate,Person-time Rates,Proportion, Incidence,Rate, Attack,Rate, Incidence,Rate, Person-time,Rate, Secondary Attack,Secondary Attack Rates
D033461 Hyperuricemia Excessive URIC ACID or urate in blood as defined by its solubility in plasma at 37 degrees C; greater than 0.42mmol per liter (7.0mg/dL) in men or 0.36mmol per liter (6.0mg/dL) in women. This condition is caused by overproduction of uric acid or impaired renal clearance. Hyperuricemia can be acquired, drug-induced or genetically determined (LESCH-NYHAN SYNDROME). It is associated with HYPERTENSION and GOUT.

Related Publications

He Huang, and Baotao Huang, and Yulin Li, and Yan Huang, and Jing Li, and Hongmei Yao, and Xianchao Jing, and Jianrong Chen, and Ji Wang
January 2021, Frontiers in medicine,
He Huang, and Baotao Huang, and Yulin Li, and Yan Huang, and Jing Li, and Hongmei Yao, and Xianchao Jing, and Jianrong Chen, and Ji Wang
January 2021, Frontiers in aging neuroscience,
He Huang, and Baotao Huang, and Yulin Li, and Yan Huang, and Jing Li, and Hongmei Yao, and Xianchao Jing, and Jianrong Chen, and Ji Wang
January 2023, Frontiers in medicine,
He Huang, and Baotao Huang, and Yulin Li, and Yan Huang, and Jing Li, and Hongmei Yao, and Xianchao Jing, and Jianrong Chen, and Ji Wang
August 2018, Atherosclerosis,
He Huang, and Baotao Huang, and Yulin Li, and Yan Huang, and Jing Li, and Hongmei Yao, and Xianchao Jing, and Jianrong Chen, and Ji Wang
January 2022, Frontiers in public health,
He Huang, and Baotao Huang, and Yulin Li, and Yan Huang, and Jing Li, and Hongmei Yao, and Xianchao Jing, and Jianrong Chen, and Ji Wang
January 2016, The Lancet. Haematology,
He Huang, and Baotao Huang, and Yulin Li, and Yan Huang, and Jing Li, and Hongmei Yao, and Xianchao Jing, and Jianrong Chen, and Ji Wang
July 2022, Acta biochimica Polonica,
He Huang, and Baotao Huang, and Yulin Li, and Yan Huang, and Jing Li, and Hongmei Yao, and Xianchao Jing, and Jianrong Chen, and Ji Wang
January 2015, Open heart,
He Huang, and Baotao Huang, and Yulin Li, and Yan Huang, and Jing Li, and Hongmei Yao, and Xianchao Jing, and Jianrong Chen, and Ji Wang
January 2021, Frontiers in cardiovascular medicine,
He Huang, and Baotao Huang, and Yulin Li, and Yan Huang, and Jing Li, and Hongmei Yao, and Xianchao Jing, and Jianrong Chen, and Ji Wang
June 2023, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology,
Copied contents to your clipboard!